AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05000021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Diabetes Distress (CBT-DD) with Continuous Glucose Monitoring
Description: CBT-DD consists of approximately 10 individual sessions of CBT delivered virtually by trained protocol therapists, conducted over the course of approximately 12 weeks. The CBT-DD consists of 5 core modules targeting negative emotionality and aversive reactions to emotional experiences. These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. The final module consists of relapse prevention. CBT-DD sessions will integrate a review of Continuous Glucose Monitoring (CGM) data and feedback will be provided by the therapist.
Study NCT05000021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Description: Use of commercially available, FDA-approved continuous glucose monitoring (CGM) for 6 months post-randomization. Usual diabetes care will continue and participants can initiate a CGM review from their healthcare providers, as desired. In addition, a nurse practitioner with expertise in CGM will train each participant via video recordings in the proper placement of the device, and technical issues, and provide basic teaching at the beginning of the trial on interpretation of CGM data and self-titration of insulin/self-management. Written materials and online resources for recognizing and managing diabetes distress, along with self-management information and treatment options to discuss with providers will also be provided.
Study NCT05000021 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitoring (CGM)
Description: Use of commercially available, FDA-approved continuous glucose monitoring (CGM) for 6 months post-randomization. Usual diabetes care will continue and participants can initiate a CGM review from their healthcare providers, as desired. In addition, a nurse practitioner with expertise in CGM will train each participant via video recordings in the proper placement of the device, and technical issues, and provide basic teaching at the beginning of the trial on interpretation of CGM data and self-titration of insulin/self-management. Written materials and online resources for recognizing and managing diabetes distress, along with self-management information and treatment options to discuss with providers will also be provided.
Study NCT06403787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerobic exercise + Ginkgo Biloba Extract
Description: 12 weeks of intervention for the participants, divided into 3 stages implementing an exercise adaptation period. The adaptation period will span the first 4 weeks of the intervention, during which participants will be brought to an intensity between 50% and 60% of their maximum heart rate (HRmax). From week 5 to 8, the HRmax range will be increased from 60% to 70%, and during the last 4 weeks, it will be maintained at 70% of HRmax combined with 240 mg of LIFE EXTENSION® brand ginkgo biloba extract in 120 mg tablets
Study NCT06403787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aerobic exercise + Calcined magnesia (placebo)
Description: 12 weeks of intervention for the participants, divided into 3 stages implementing an exercise adaptation period. The adaptation period will span the first 4 weeks of the intervention, during which participants will be brought to an intensity between 50% and 60% of their maximum heart rate (HRmax). From week 5 to 8, the HRmax range will be increased from 60% to 70%, and during the last 4 weeks, it will be maintained at 70% of HRmax combined with calcined magnesia (homogenized to the same weight of ginkgo biloba)
Study NCT06403787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise + Atorvastatin
Description: 12 weeks of intervention for the participants, divided into 3 stages implementing an exercise adaptation period. The adaptation period will span the first 4 weeks of the intervention, during which participants will be brought to an intensity between 50% and 60% of their maximum heart rate (HRmax). From week 5 to 8, the HRmax range will be increased from 60% to 70%, and during the last 4 weeks, it will be maintained at 70% of HRmax combined with 20 mg of atorvastatin
Study NCT06472518 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pharmaco mechanical thrombolysis
Description: arm with the pharmaco mechanical thrombolysis intervention combined with anticoagulant treatment with direct oral anticoagulants
Study NCT06472518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pharmaco mechanical thrombolysis
Description: arm with the pharmaco mechanical thrombolysis intervention combined with anticoagulant treatment with direct oral anticoagulants
Study NCT05440097 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: QIP intervention
Description: The QIP includes pulmonologist-targeted guideline education and guideline implementation.~Guideline education includes the initial comprehensive training and reinforcement learning. The initial comprehensive education will be delivered at each participating hospital by a dedicated national asthma expert team, immediately after last patient enrolled at each site. The PI of respiratory departments from participating hospitals are responsible for arranging the delivery of hospital-level reinforcement learnings and ensuring the quality and success of hospital-level guideline implementation.~The pulmonologists' guideline adherence and performance at participating hospitals will be regularly assessed during the study period.
Study NCT06178419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIC
Description: RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on unilateral arms. The RIC protocol includes five cycles of 5-min inflation to 200mmHg and 5-min deflation.
Study NCT06178419 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-RIC
Description: Sham-RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on unilateral arms. The sham RIC protocol includes five cycles of 5-min inflation to 60mmHg and 5-min deflation.
Study NCT05624606 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza mRNA Vaccine MRT5410
Description: Pharmaceutical form: Liquid frozen solution for injection in a vial Route of administration: Intramuscular
Study NCT05624606 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Recombinant Influenza vaccine RIV4
Description: Pharmaceutical form: Liquid suspension for injection in prefilled syringe Route of administration: Intramuscular
Study NCT05624606 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Inactivated Influenza Standard Dose QIV-SD
Description: Pharmaceutical form: Liquid suspension for injection in prefilled syringe Route of administration: Intramuscular
Study NCT05624606 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Inactivated Influenza High Dose QIV-HD
Description: Pharmaceutical form: Liquid suspension for injection in prefilled syringe Route of administration: Intramuscular
Study NCT05834634 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound
Description: The patients and controls will be scanned at the Neurophysiology unit of the Department of Neurology, Neurology, psychiatry and Neurosurgery hospital, Assiut university hospital. The acquisition of ultrasound images was performed using a Philips HD11XE imaging system with an L12-8 linear array probe. Cross-sectional area (CSA) of the right and left Vagus nerves in each subject, perimeter, echogenicity, and fascicular structure will be assessed and measured by tracing the nerve just inside its hyperechoic rim. The nerve will be seen on ultrasound B-mode near the bifurcation of the carotid artery, dorsal to the internal and common carotid arteries, as a structure that is hypoechogenic in the centre and more hyperechogenic on the periphery (24, 25). Both the carotid artery and the internal jugular vein served as anatomical landmarks (25). Two separate CSA measurements, with the probe repositioned for each measurement, will be taken and they will be averaged.
Study NCT05150028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient participation
Description: Questionnaire
Study NCT05150028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinician barrier reports
Description: How many times a 7 question Survey on medication education practices is opened
Study NCT05195398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal transcranial Direct Current Stimulation (A-tDCS)
Description: Participants randomized to tDCS will undergo 5 weeks of A-tDCS + CCT.
Study NCT05195398 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Intervention
Description: Participants randomized to sham-intervention will undergo 5 weeks of sham + CCT.
Study NCT04970134 — intervention group
Intervention type: OTHER
Intervention: Immunohistochemistry (IHC)
Description: VENTANA pan-TRK technique (EPR17341) Assay, with Optiview DAB-detection kit and Optiview amplification kit. Using FFPE slices
Study NCT04970134 — intervention group
Intervention type: OTHER
Intervention: Fluorescence In-Situ Hybridization (FISH)
Description: FISH using FFPE slices for genes: Neurotrophic tyrosin kinase 1 (NTRK1), Neurotrophic tyrosin kinase 3 (NTRK3) and rearranged during transfection (RET)
Study NCT04970134 — intervention group
Intervention type: OTHER
Intervention: Oncomine Focus Assay Platform with 52 genes
Description: Oncomine Focus Assay Platform with 52 genes (35 Hotspot genes, 19 Copy number variants and 23 Gene fusions). Using FFPE slices
Study NCT05124925 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ianalumab
Description: Ianalumab VAY736 150mg/1ml Solution for injection
Study NCT04759274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diuretic Tuner
Description: Mobile device application for diuretic dose titration
Study NCT06420882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The experimental group.
Description: In the experimental group, in addition to home exercises, patella mobilization, muscle strengthening exercises, range of motion exercises and home exercises will be performed 3 days a week for 3 sessions with a therapist.
Study NCT06420882 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The home exercise group
Description: Participants in both groups will be included in a 3-week treatment programme.
Study NCT05845385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar epidural analgesia with bupivacaine
Description: postoperative analgesic method
Study NCT05845385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transversus abdominis plane block with bupivacaine
Description: postoperative analgesic method
Study NCT05845385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: wound infiltration with bupivacaine
Description: postoperative analgesic method
Study NCT04096430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENGAGE approach (child-oriented goal-setting)
Description: See description of experimental arm.
Study NCT05355532 — intervention group
Intervention type: GENETIC
Intervention: different variants of SNPs that may be associated with the coronary microvascular obstruction development
Description: Some variants of SNPs determine endothelial function, microcirculation, hemostasis, and inflammation in MI patients. They may be associated with the development of coronary microvascular obstruction during emergency PCI. A link between the different SNPs and the CMVO development will be established. SNP will be determined by real-time polymerase chain reaction with high-resolution melting curve analysis using TaqMan fluorescent probes.
Study NCT05626738 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENDORAIL
Description: In case caecal intubation time is longer than 10 minutes, the balloon catheter is inserted in the tool channel, advanced beyond the colonoscope tip and filled with Ferromagnetic Fluid. By applying the Endorail Handpiece over the patient abdomen, the balloon can be magnetically anchored. The anchored balloon guide allows to straighten the scope and the colon itself. The colonoscope can thus be easily moved back and forward along the anchored guide to facilitate colonoscope positioning and colonoscopy completion. Afterward, Endorail is removed and the straightened colonoscope can be easily pushed forward to achieve colonoscopy completion according to standard endoscopic technique.
Study NCT05884554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07817883
Description: Experimental
Study NCT05425979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine
Description: Up to two 30 ml vials of mepivacaine 1.5% via ultrasound-guided nerve blockade of the tibial and deep peroneal nerves
Study NCT05425979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Up to two 30 ml vials of bupivacaine 0.5% via ultrasound-guided nerve blockade of the tibial and deep peroneal nerves
Study NCT06367764 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: Cognitive Processing Therapy teaches cognitive restructuring skills to help clients change beliefs and process emotions related to a traumatic event or events.
Study NCT06367764 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STAIR Narrative Therapy
Description: STAIR Narrative Therapy teaches coping skills (e.g., for emotional regulation, interpersonal relationships, everyday stress) and includes a narrative trauma-focused component.
Study NCT06507943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotora Home Visit
Description: For each participating family, Promotora home visits will be scheduled 6-8 weeks apart, with in-person or virtual visits conducted per the family's preference. The visits will begin with a survey which will evaluate concerns related to asthma for the child and the family, including their asthma control (via the ACT), their home environment (via screening for environmental exposures), and quality of life for the child. These surveys will be available in both online or physical forms for potential connectivity concerns, and Promotoras will have IPads for the online forms. The Promotoras, who have received specialized asthma training, will then address concerns raised by families, using the Clinical Pathway which will have resources for asthma-related concerns that are raised.
Study NCT04909710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Game System for Potential Treatment of Developmental Delays
Description: Mobile game system meant to generate valuable data for measuring progress and building novel artificial intelligence models while delivering impactful education for and treatment of children with developmental delays such as autism.
Study NCT04909710 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mobile Game System for Potential Treatment of Developmental Delays
Description: Mobile game system meant to generate valuable data for measuring progress and building novel artificial intelligence models while delivering impactful education for and treatment of children with developmental delays such as autism.
Study NCT04709068 — intervention group
Intervention type: DEVICE
Intervention: Current Health
Description: wearable device and tablet used to collect health measures at home
Study NCT05228470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: BCMA-CD3 bispecific antibody
Study NCT04776395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT04776395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO
Study NCT04776395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide Hydrochloride
Description: Given PO
Study NCT04776395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iberdomide Hydrochloride
Description: Given PO
Study NCT04776395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04776395 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05989009 — intervention group
Intervention type: OTHER
Intervention: Breastfeeding
Description: Mothers will breastfeed their newborns
Study NCT05891704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand therapy Rehabilitation intervention program that incorporate cultural reference
Description: The intervention will provide a conventional hand therapy rehabilitation intervention program that incorporates cultural reference based on Focused Acceptance and commitment Therapy ( FACT).
Study NCT05891704 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Hand therapy Rehabilitation intervention program
Description: The intervention will provide a conventional hand therapy rehabilitation intervention program
Study NCT06572683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression. Using pulsed magnetic fields, transcranial magnetic stimulation therapy stimulates the part of the brain thought to be involved with mood regulation. These magnetic fields do not directly affect the whole brain; they only reach about 2-3 centimeters into the brain directly beneath the treatment coil.As these magnetic fields move into the brain, they produce very small electrical currents. These electrical currents activate cells within the brain, causing them to rewire, a process called neuroplasticity.
Study NCT04592874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL002
Description: Administered via intravenous (IV) infusion
Study NCT04592874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via intravenous (IV) infusion
Study NCT04788888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navitor Transcatheter Aortic Valve and FlexNav Delivery System
Description: For traditional application, the Navitor valve is indicated for transcatheter delivery in patients with symptomatic severe native aortic stenosis who are intermediate or low surgical risk.~For the valve-in-valve application, the Navitor valve is indicated for use in patients with symptomatic heart disease due to failure (stenosed, insufficient, or combined) of a surgical bioprosthetic aortic valve.~Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Navitor valve and FlexNav Delivery system
Study NCT06569368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Given by PO
Study NCT04196777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit-and-feedback
Description: We will provide feedback both at baseline and at regular intervals to the 3 intervention sites. At first, we will schedule one-on-one conference calls with urology providers and the antimicrobial stewardship team at each of the 3 intervention sites. These conference calls will include a review of guidelines, a review of the facility's data on excessive post-procedural antimicrobial use for urologic patients, and an anonymous comparison to all other VHA sites. Next, we will prospectively monitor excessive post-procedural antimicrobial use at all 3 sites and the entire VHA for 1 year. Data on hospital-level excessive post-procedural antimicrobial use specific to urologic patients (primary outcome) will be sent electronically to urology providers and the antimicrobial stewardship team at the intervention site every other month via electronic mail.
Study NCT04942717 — intervention group
Intervention type: BEHAVIORAL
Intervention: CONVO intervention
Description: The CONVO intervention consists of oncology nurse-led discussions exploring patients' health-related values as part of routine oncology care for all patients, from the beginning of oncologic care. Nurses will use the Nurse's Values Discussion Guide. At these sites, chemotherapy nurses will deliver the CONVO discussion, as patients at these sites do not have primary nurses assigned and because oncology doctors, BPs and PAs do not work one-on-one as a pair with a unique nurse.
Study NCT05412901 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: discrimination task
Description: Participants perform a discrimination task while their brain activity is recorded with EEG. Beta power will be estimated using spectral decomposition techniques, zooming in on subject specific bands in temporospatial windows of interest, and correlated with (1) WM content, (2) decision outcome, and (3) behavioral performance (i.e., accuracy and RT).
Study NCT04729907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nusinersen
Description: Administered as specified in the treatment arm
Study NCT05442749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Eligible patients will receive niraparib once daily, per os, continuously until loss of clinical benefit, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first.~300 mg/day, continuously for patients with TB >1.5- 3 ULN and/or ASAT/ALAT ≤5ULN.~Or 200mg/day initial dosing for patients with TB >1.5 ULN and up to 3ULN and/or ASAT/ALAT > 2.5 ULN and up to 5 ULN with increase to 300mg/day if 1) liver safety lab tests improve to Grade 1 according to NCI criteria (based on total bilirubin and AST/ALT) with bilirubin \< 1.5ULN) and 2) no grade >1 related AE are reported.
Study NCT05315102 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: The participants head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The sham intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust